The Natco Pharma share price grabbed attention in the stock market today after the company announced a major regulatory approval. Investors reacted quickly. The stock surged more than 11% on February 16, reflecting strong market sentiment around its latest product launch plan.
The trigger? Approval to manufacture and market generic Semaglutide injection in India.
Let’s break down what happened and why the street responded the way it did.
Market Performance: Natco Pharma Share Price Surges
In the stock market today, Natco Pharma shares saw sharp buying interest.
At 11 AM on February 16:
- Natco Pharma share price was trading 11.6% higher
- The stock was quoted at ₹919.3 per share
The rally came after the company disclosed regulatory approval for a key diabetes and weight management drug. The momentum in the Natco Pharma share price was clear and supported by strong volumes during the session.
Meanwhile, in the broader pharma pack:
- Nifty Pharma index rose nearly 1%
- Sector sentiment remained positive throughout the morning trade
The Natco Pharma share price outperformed the sector index in the stock market today, driven by company-specific developments.
Main News: Approval to Launch Semaglutide in India
Natco Pharma informed the exchanges on February 14 about a regulatory milestone.
Here’s what the company disclosed:
- Approval received from CDSCO
- Permission to manufacture and market generic Semaglutide Injection
- Commercial launch planned for March 2026
- Indication: Prescribed for adults whose Type 2 diabetes is not adequately controlled, to be used along with diet and exercise.
- To be used as an adjunct to diet and exercise
Semaglutide is widely used in managing:
- Chronic weight
- Type-2 diabetes
The news immediately influenced the Natco Pharma share price in the stock market today.
Regulatory approvals in pharma are often seen as growth triggers. In this case, the approval opens access to the India market for a high-demand therapy category.
The strong reaction in the Natco Pharma share price reflects how closely the market tracks product pipelines and launch timelines.
Financial Performance: December Quarter Snapshot
Apart from the Semaglutide approval, recent quarterly numbers also remained part of investor focus.
For the quarter ended December 31, 2025:
Net Profit
- Consolidated net profit stood at ₹151 crore
- Up 14% year-on-year
- Compared to ₹132 crore in the year-ago quarter
Revenue from Operations
- Revenue rose to ₹647 crore
- Compared to ₹475 crore in the same quarter last fiscal
The numbers show year-on-year growth in both revenue and profit. This backdrop added strength to the sentiment surrounding the Natco Pharma share price in the stock market today.
Dividend Announcement
Natco Pharma also announced a shareholder reward.
The company’s board declared:
- Third interim dividend
- ₹1.5 per share
- For the financial year 2025–26
Dividend announcements often add to investor confidence, especially when supported by improving financial performance.
Board Decisions and Expansion Plans
Along with earnings and product approval updates, the board made key decisions:
- Re-appointment of Venkaiah Chowdary Nannapaneni as Chairman and Managing Director
- Term of one year
- Effective from April 1, 2026
- Approval to incorporate a wholly-owned subsidiary in Chile
- Investment of up to $300,000
Global expansion and leadership continuity were also noted in the filings. These updates formed part of the broader narrative influencing the Natco Pharma share price in the stock market today.
Sectoral Movement in Stock Market Today
On February 16:
- Nifty Pharma gained nearly 1%
- Pharma stocks remained active in early trade
The Natco Pharma share price outperformed the sector index during the session, supported by company-specific developments rather than just broader market movement.
Why Natco Pharma Share Price Reacted Sharply?
In the stock market today, the reaction was immediate and strong. The key reasons:
- Regulatory approval for Semaglutide
- Clear launch timeline – March 2026
- 14% year-on-year growth in quarterly net profit
- Revenue growth from ₹475 crore to ₹647 crore
- Dividend announcement
- International subsidiary approval
Each factor added to overall sentiment.
The rally in the Natco Pharma share price shows how regulatory news combined with financial growth can influence stock movement within a single trading session.
Summary: Natco Pharma Share Price in Focus
To recap the developments impacting the Natco Pharma share price in the stock market today:
- Stock jumped over 11%
- Traded at ₹919.3 at 11 AM on February 16
- Received approval to launch generic Semaglutide injection in India
- Launch scheduled for March 2026
- Q3 net profit rose to ₹151 crore (up 14% YoY)
- Revenue increased to ₹647 crore
- Declared interim dividend of ₹1.5 per share
- Approved Chile subsidiary with up to $300,000 investment
In the stock market today, few stocks managed to capture attention the way Natco did. Regulatory progress, financial growth, and board-level decisions collectively shaped the day’s sentiment.
The Natco Pharma share price remains in focus as markets track further updates around the upcoming product launch and quarterly developments.
Source: Moneycontrol
Easy & quick
Leave A Comment?